Kalvista Market Capitalization from 2010 to 2024
| KALV Stock | USD 10.06 0.03 0.30% |
Check Kalvista Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kalvista Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 424 K, Interest Expense of 0.0 or Selling General Administrative of 4.9 M, as well as many indicators such as Price To Sales Ratio of 46.33, Dividend Yield of 0.0 or Days Sales Outstanding of 268. Kalvista financial statements analysis is a perfect complement when working with Kalvista Pharmaceuticals Valuation or Volatility modules.
Kalvista | Market Capitalization |
Latest Kalvista Pharmaceuticals' Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Kalvista Pharmaceuticals over the last few years. It is Kalvista Pharmaceuticals' Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kalvista Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 496.58 M | 10 Years Trend |
|
Market Cap |
| Timeline |
Kalvista Market Capitalization Regression Statistics
| Arithmetic Mean | 144,883,259 | |
| Geometric Mean | 108,576,691 | |
| Coefficient Of Variation | 85.09 | |
| Mean Deviation | 94,347,313 | |
| Median | 91,099,110 | |
| Standard Deviation | 123,278,229 | |
| Sample Variance | 15197.5T | |
| Range | 427.9M | |
| R-Value | 0.60 | |
| Mean Square Error | 10549.9T | |
| R-Squared | 0.36 | |
| Significance | 0.02 | |
| Slope | 16,433,421 | |
| Total Sum of Squares | 212765.3T |
Kalvista Market Capitalization History
About Kalvista Pharmaceuticals Financial Statements
Kalvista Pharmaceuticals investors use historical fundamental indicators, such as Kalvista Pharmaceuticals' Market Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kalvista Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks KVD824, an oral product candidate for the treatment of HAE and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. Kalvista Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.